$1.06
+0.04 (+3.92%)
Open$1.02
Previous Close$1.02
Day High$1.09
Day Low$1.02
52W High$8.69
52W Low$0.92
Volume—
Avg Volume145.6K
Market Cap133.63M
P/E Ratio—
EPS$-16.83
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,746.2% upside
Current
$1.06
$1.06
Target
$40.77
$40.77
$30.54
$40.77 avg
$54.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.62M | 1.61M |
| Net Income | -161,760 | -172,924 | -142,728 |
| Profit Margin | -9.5% | -10.7% | -8.9% |
| EBITDA | -256,082 | -275,942 | -257,647 |
| Free Cash Flow | -132,527 | -99,336 | -105,630 |
| Rev Growth | +0.4% | +1.6% | -5.5% |
| Debt/Equity | 0.26 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |